Clinical trials: MASLD
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Deep Learning for Liver Fibrosis Triage in MASLD Using Longitudinal Electronic Health Records
This study looks at a new computer program called NIMIT-AI (Neural Inference for Metabolic-liver Integrated Trajectories, Artificial Intelligence) that helps doctors find liver scarring early in patients with fatty liver disease.
- Trial name
- NIMIT-AI (NCT07675525)
- Testing
- Longitudinal electronic health record analysis
- Where
- Thailand
- Volunteers
- 1,351 people
- Sponsor
- Siriraj Hospital
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity
The objective of this study is to demonstrate that an < or equal to 8-hour time-restricted eating (i.e., fasting for at least 16 hours every day), not focusing on reducing caloric intake, reduces intra-hepatic fat in patients…
- Trial name
- CHRONOSTEATOSI (NCT07378072)
- Testing
- Time Restricted Eating, Usual care only
- Where
- 9 sites in France
- Volunteers
- 72 people
- Sponsor
- Nantes University Hospital
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
Overall design: The study will include one intervention based on Mediterranean diet plus structured lifestyle intervention (150 min/week of moderate-intensity or 75 min/week of high-intensity exercise) for a total of 16 weeks.
- Trial name
- UNMASK (NCT07652151)
- Testing
- Multimodal lifestyle intervention
- Where
- 3 sites in Italy, Spain and 1 more
- Volunteers
- 450 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
MASLD
FIB-4 Cut-Offs for Liver Fibrosis in Obese Endocrinology Patients
This single-center, prospective observational study aims to assess the accuracy of FIB-4 cut-offs in identifying liver fibrosis in obese patients attending an endocrinology outpatient clinic in Italy.
- Trial name
- OBEMASLD (NCT07663188)
- Volunteers
- 400 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated…
- Trial name
- MASLD-GUT (NCT07313007)
- Testing
- stool sampling, dietary assessment, and collection of blood and urine samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
MASLD, HIV (Human Immunodeficiency Virus)
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is increasingly prevalent worldwide.
- Trial name
- MASLD (NCT07640880)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yinzhong Shen
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Early Motherhood
Temporal Eating Patterns and Metabolic Health
Obesity and its related health problem, like fatty liver disease and type 2 diabetes, are major health problems worldwide and can lead to serious illness and reduced quality of life.
- Trial name
- TIME-MET (NCT07630636)
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Maria Chondronikola
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Trial name
- NCT06735924
- Testing
- Low-oxalate fixed diet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University
MASLD
Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to evaluate the effect of Ancestry, a supplement made from Mexican-origin foods (nopal, cacao, and cricket) in adults with Metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- Ancestry (NCT07592013)
- Testing
- Ancestry
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- University of Guadalajara
MASLD, Chronic Kidney Diseases
Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.
Renal dysfunction is a frequent and clinically important complication in cirrhosis, and MASLD/NAFLD is associated with increased risk of incident CKD; however, finerenone has not been specifically studied in MASLD-cirrhosis…
- Trial name
- NCT07585526
- Testing
- Finerenone, Spironolactone, Standard Medical Treatment
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
This study proposes a single-blind randomized clinical trial designed to evaluate the effects of high-intensity interval training (HIIT) on liver health in adults with overweight or obesity, while also assessing the usefulness of…
- Trial name
- RENACE (NCT07552727)
- Testing
- High-intensity interval training
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Universidad San Sebastián
Obesity & Overweight, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Adherence and Tolerability of Four Very Low-Calorie Ketogenic Diet Approaches in Adults With Obesity or Complicated Overweight
This study, called KOBE Study, looks at how well different very low-calorie ketogenic diets (VLCKD) are followed and tolerated by adults with obesity or complicated overweight in routine clinical practice.
- Conditions
- Obesity & Overweight, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Type 2 Diabetes, Insulin Resistance
- Trial name
- KOBE (NCT07389122)
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- University of Bologna
NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
- Trial name
- NCT06161571
- Testing
- Efruxifermin
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 700 people
- Sponsor
- Akero Therapeutics, Inc
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI > 25)
- Trial name
- NCT07193927
- Testing
- Lactiplantibacillus plantarum Probiotic Mixture
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- AB Biotics, SA